New blood test to detect 20 types of cancers developed
A new blood test has shown ability to screen numerous
types of cancer with a high degree of accuracy. A trial of the test showed it
detected and localised more than 20 types of cancers.
The test, developed by biotechnology company Grail Inc
uses next-generation sequencing technology to probe DNA for tiny chemical tags
(methylation) that influence whether genes are active or inactive.
When applied to nearly 3,600 blood samples — some from
patients with cancer and some from people who had not been diagnosed with cancer at the time of the blood
draw — the test successfully picked up a cancer signal from the cancer patient
samples, and correctly identified the tissue from where the cancer began (the
tissue of origin),” said investigators from Boston-based Dana-Farber Cancer
Institute.
The test’s specificity – its ability to return a positive result only when cancer is actually present – was high, as was its
ability to pinpoint the organ or tissue of origin, they found.
The new test looks for DNA, which cancer cells shed
into the bloodstream when they die.
In contrast to “liquid biopsies,” which detect genetic mutations or other cancer-related alterations in DNA, the technology focuses on modifications to DNA known as methyl groups.
In contrast to “liquid biopsies,” which detect genetic mutations or other cancer-related alterations in DNA, the technology focuses on modifications to DNA known as methyl groups.
Methyl groups are chemical units that can be attached
to DNA, in a process called methylation, to control which genes are “on” and
which are “off.” Abnormal patterns of methylation turn out to be, in many
cases, more indicative of cancer – and cancer type — than mutations are.
“Our previous work indicated that methylation-based
assays outperform traditional DNA-sequencing approaches to detecting multiple
forms of cancer in blood samples,” said the study’s lead author Geoffrey Oxnard
from Dana-Farber.
30.09.2019
Replace every
negative thought with a positive one
No comments:
Post a Comment